Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies.
AHA
APA
anti-PD-1
anti-PD-L1
anti-hypothalamus antibodies
anti-pituitary antibodies
pituitary autoimmunity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
11 Aug 2021
11 Aug 2021
Historique:
received:
14
06
2021
revised:
26
07
2021
accepted:
09
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Autoimmune hypophysitis is a frequent immune-related adverse event (irAE) in cancer patients treated with immunecheckpoint inhibitors. Studies seeking anti-pituitary (APA) and anti-hypothalamus (AHA) antibodies in patients treated with anti-PD-1 and anti-PD-L1 are scarce. The aim of this study is to search for APA and AHA and related pituitary dysfunction in patients treated with these agents. Cross-sectional and preliminary longitudinal studies were conducted at the Medical Oncology Unit and Endocrinology and Metabolic Diseases Unit of the University of Campania "Luigi Vanvitelli". Fifty-four cancer patients on treatments with anti-PD-1 or anti-PD-L1 (Group 1) and 50 healthy controls were enrolled for a cross-sectional study; 13 cancer patients (Group 2) were enrolled for our preliminary longitudinal study. APA/AHA titers and changes in biochemical and hormonal profile were evaluated in Group 1; in Group 2, they were evaluated before and after nine weeks from the start of immunotherapy. Patients of Group 1 showed a higher prevalence of APA and AHA than controls: 21 of them had APA, 16 had AHA, and 11 had both autoantibodies. In total, 7 of 13 patients in Group 2 became APA-positive and 3 became AHA-positive after nine weeks of immunotherapy, showing an increase in prolactin and a decrease in ACTH and IGF-1 levels compared with basal values. Anti-pituitary and anti-hypothalamus antibodies seem to play a pivotal role in hypothalamic-pituitary autoimmunity and secondary endocrine-related alterations evoked by anti-PD-1 and PD-L1 antibodies.
Sections du résumé
BACKGROUND
BACKGROUND
Autoimmune hypophysitis is a frequent immune-related adverse event (irAE) in cancer patients treated with immunecheckpoint inhibitors. Studies seeking anti-pituitary (APA) and anti-hypothalamus (AHA) antibodies in patients treated with anti-PD-1 and anti-PD-L1 are scarce. The aim of this study is to search for APA and AHA and related pituitary dysfunction in patients treated with these agents.
METHODS
METHODS
Cross-sectional and preliminary longitudinal studies were conducted at the Medical Oncology Unit and Endocrinology and Metabolic Diseases Unit of the University of Campania "Luigi Vanvitelli". Fifty-four cancer patients on treatments with anti-PD-1 or anti-PD-L1 (Group 1) and 50 healthy controls were enrolled for a cross-sectional study; 13 cancer patients (Group 2) were enrolled for our preliminary longitudinal study. APA/AHA titers and changes in biochemical and hormonal profile were evaluated in Group 1; in Group 2, they were evaluated before and after nine weeks from the start of immunotherapy.
RESULTS
RESULTS
Patients of Group 1 showed a higher prevalence of APA and AHA than controls: 21 of them had APA, 16 had AHA, and 11 had both autoantibodies. In total, 7 of 13 patients in Group 2 became APA-positive and 3 became AHA-positive after nine weeks of immunotherapy, showing an increase in prolactin and a decrease in ACTH and IGF-1 levels compared with basal values.
CONCLUSIONS
CONCLUSIONS
Anti-pituitary and anti-hypothalamus antibodies seem to play a pivotal role in hypothalamic-pituitary autoimmunity and secondary endocrine-related alterations evoked by anti-PD-1 and PD-L1 antibodies.
Identifiants
pubmed: 34439190
pii: cancers13164036
doi: 10.3390/cancers13164036
pmc: PMC8391584
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Oncol. 2018 Feb 1;4(2):173-182
pubmed: 28973656
Thyroid. 2020 Feb;30(2):177-184
pubmed: 31813343
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
J Clin Endocrinol Metab. 2012 Oct;97(10):3684-90
pubmed: 22855340
Int J Mol Sci. 2020 Feb 19;21(4):
pubmed: 32092880
Pituitary. 2016 Feb;19(1):82-92
pubmed: 26186958
Endocr Rev. 2005 Aug;26(5):599-614
pubmed: 15634713
Eur J Endocrinol. 2016 Mar;174(3):381-7
pubmed: 26598530
Thyroid. 2016 Aug;26(8):1117-24
pubmed: 27296629
Eur J Endocrinol. 2003 Nov;149(5):363-76
pubmed: 14585081
Clin Endocrinol (Oxf). 2016 Sep;85(3):331-9
pubmed: 26998595
Immunotherapy. 2018 Mar 1;10(6):427-431
pubmed: 29562858
J Clin Endocrinol Metab. 2001 Mar;86(3):1048-53
pubmed: 11238484
Nat Rev Endocrinol. 2017 Apr;13(4):195-207
pubmed: 28106152
Endocrinol Diabetes Metab Case Rep. 2019 Oct 12;2019:
pubmed: 31610523
J Int Med Res. 2020 Mar;48(3):300060519887832
pubmed: 31779500
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e415-e429
pubmed: 33104773
Pituitary. 2019 Jun;22(3):236-248
pubmed: 30847776
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Clin Endocrinol Metab. 2015 May;100(5):1738-41
pubmed: 25751110
Autoimmun Rev. 2008 Sep;7(8):631-7
pubmed: 18774118
J Endocrinol Invest. 2020 Mar;43(3):337-345
pubmed: 31542865
Am J Pathol. 2016 Dec;186(12):3225-3235
pubmed: 27750046
Horm Metab Res. 2019 Mar;51(3):145-156
pubmed: 30861560
J Clin Endocrinol Metab. 2016 Mar;101(3):769-77
pubmed: 26908107
Pituitary. 2014 Oct;17(5):457-63
pubmed: 24122272
Cancer Treat Rev. 2017 Jul;58:70-76
pubmed: 28689073
BMC Med. 2015 Sep 04;13:211
pubmed: 26337719
Front Endocrinol (Lausanne). 2020 Feb 18;11:16
pubmed: 32132974
Cell Mol Immunol. 2019 Jun;16(6):625-626
pubmed: 30979971
Pituitary. 2016 Dec;19(6):625-642
pubmed: 27503372
Eur J Endocrinol. 2019 Sep;181(3):211-219
pubmed: 31176301
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Future Oncol. 2019 Sep;15(27):3159-3169
pubmed: 31423850
Eur J Endocrinol. 2018 Feb;178(2):173-180
pubmed: 29187509
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Pituitary. 2010;13(1):29-38
pubmed: 19639414
Diabetes. 2018 Aug;67(8):1471-1480
pubmed: 29937434
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
J Clin Endocrinol Metab. 2003 Feb;88(2):650-4
pubmed: 12574195
J Dermatol. 2016 Feb;43(2):210-4
pubmed: 26198822
Eur J Cancer. 2018 Nov;104:247-249
pubmed: 30377030
Expert Rev Endocrinol Metab. 2019 Nov;14(6):381-398
pubmed: 31842671
Lancet Diabetes Endocrinol. 2013 Nov;1(3):e15
pubmed: 24622375